Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Announces Veyonda COVID-19 Study Approved For Immediate Start (ASX:NOX)

Australian drug development companyNoxopharm Limited (ASX: NOX) today announces the commencement of a clinical study of Veyonda® in COVID-19 patients. Following review by expert panels, official...read more

Noxopharm Announces Peer-Reviewed Publication Strengthens Case for Veyonda (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the publication of the first manuscript of the LuPIN trial in the journal, European Urology Onco...read more

Noxopharm Announces Data Shows Idronoxil Holds Key to Problem of COLD Cancers (ASX:NOX)

Important pre-clinical data from two independent research groups confirms that idronoxil (IDX), the active ingredient in Veyonda, achieves a major goal in restoring cancer-fighting immune function w...read more

Nyrada Brain Injury Drug Pharmacokinetic Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) reports results from a preclinical pharmacokinetic study of its two lead Brain Injury drug candidates. Both candidates have achieved durable therapeutic levels when administere...read more

Nyrada Cholesterol-Lowering Drug Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging preclinical results from its cholesterol-lowering program to develop a drug to treat hypercholesterolemia. A study using healthy donor human...read more

Viewing: 196 - 210 of 200 Previous | Next